Amikacin

Overview

Amikacin is a systemic aminoglycoside antibiotic used in dogs and cats for the treatment of serious bacterial infections. It is administered parenterally and is particularly valued for its activity against aerobic gram-negative organisms and some gram-positive bacteria, including staphylococci.

Due to the inherent toxicity associated with aminoglycosides, amikacin is reserved for severe infections in which less toxic antibiotics are ineffective or when immediate empirical treatment of suspected gram-negative infections is clinically justified before culture and susceptibility results are available.

Amikacin is a concentration-dependent, bactericidal antibiotic. In dogs and cats, once-daily dosing is generally preferred, as this regimen achieves higher peak plasma concentrations, enhances bacterial killing, and may reduce the risk of adaptive resistance while allowing drug-free intervals that help limit toxicity.

Indications

In dogs and cats, systemic amikacin is used for the treatment of serious bacterial infections caused by susceptible organisms, particularly when alternative, less toxic antibiotics are ineffective or inappropriate.

• Serious gram-negative infections: Used for infections caused by aerobic gram-negative bacilli, especially in critically ill patients or when multidrug resistance is suspected.
• Staphylococcal infections: May be used for severe infections caused by susceptible staphylococci when other antimicrobial options are limited.
• Empirical therapy in severe infections: Employed as initial empirical treatment for life-threatening infections when immediate coverage of gram-negative organisms is required before culture and susceptibility results are available.
• Resistant infections: Considered when bacteria are resistant to other aminoglycosides or less toxic antimicrobial classes.

Dosage (Reference)

Dog

In dogs, systemic amikacin is used extra-label for the treatment of serious infections caused by susceptible bacteria. Due to the risk of nephrotoxicity and ototoxicity, dosing must be individualized and renal function carefully monitored.

Cat

In cats, amikacin is used extra-label for serious bacterial infections. Cats may be more sensitive to the toxic effects of aminoglycosides, and conservative dosing with close monitoring is essential.

Warnings & Precautions

Amikacin is a potent aminoglycoside antibiotic with a narrow safety margin. Its use in dogs and cats requires careful patient selection, appropriate dosing intervals, and close monitoring to minimize the risk of serious adverse effects.

• Nephrotoxicity risk: Use with extreme caution in dogs and cats with pre-existing renal disease. Renal function should be evaluated before and during therapy, and dosing intervals adjusted as needed.
• Ototoxicity: Aminoglycosides can cause irreversible auditory or vestibular toxicity. Cats may be particularly sensitive to vestibular effects. Monitor for hearing loss, head tilt, nystagmus, or balance disturbances.
• Patient risk factors: Increased risk of toxicity is associated with neonatal or geriatric age, dehydration, fever, sepsis, and hypovolemia.
• Neuromuscular blockade: Use cautiously in animals with neuromuscular disorders, as amikacin can potentiate neuromuscular weakness.
• Dosing strategy: Once-daily dosing is preferred to reduce renal accumulation and toxicity compared with multiple daily dosing regimens.
• Hydration status: Ensure patients are adequately hydrated before and during treatment to reduce the risk of nephrotoxicity.
• Injection considerations: Pain and inflammation may occur at injection sites; rotate injection sites when possible.
• Breed considerations: Sight hounds may require dose adjustments due to differences in drug distribution.

Drug Interactions

Clinically significant drug interactions with amikacin in dogs and cats are primarily related to additive nephrotoxicity, ototoxicity, or potentiation of neuromuscular blockade. Careful evaluation and monitoring are required when amikacin is combined with the following medications.

• Other nephrotoxic drugs (e.g., amphotericin B, cisplatin, polymyxin B, vancomycin): Concurrent use increases the risk of renal injury and should be avoided when possible.
• NSAIDs (e.g., carprofen, meloxicam, firocoxib, robenacoxib): May increase the risk of nephrotoxicity, particularly in dehydrated or critically ill patients.
• Loop diuretics (e.g., furosemide, torsemide): Increased risk of ototoxicity and nephrotoxicity when used concurrently.
• Osmotic diuretics (e.g., mannitol): May potentiate ototoxic and nephrotoxic effects of aminoglycosides.
• Neuromuscular blocking agents (e.g., atracurium, pancuronium): Concurrent use may enhance neuromuscular blockade and respiratory depression.
• General anesthetic agents (e.g., isoflurane, propofol, ketamine): May potentiate neuromuscular blockade during anesthesia.
• Magnesium-containing products: Systemic magnesium may increase the risk of neuromuscular blockade.
• Penicillins: May have synergistic antibacterial effects against some organisms; however, physical incompatibility can occur—do not mix in the same syringe or IV solution.
• Cephalosporins: Potential for additive nephrotoxicity exists, although this is rarely clinically significant with modern agents; assess risk versus benefit.

Side Effects & Overdose

Side Effects

Adverse effects associated with systemic amikacin in dogs and cats are primarily dose- and duration-dependent and relate to renal, auditory, vestibular, and neuromuscular toxicity. Close monitoring throughout therapy is essential.

• Nephrotoxicity: The most clinically significant adverse effect. Manifested by increases in serum creatinine and BUN, decreased urine concentrating ability, proteinuria, and abnormal urine sediment. Renal toxicity is usually nonoliguric and often reversible if detected early and the drug is discontinued.
• Ototoxicity: May present as hearing loss and/or vestibular dysfunction. Vestibular signs (e.g., head tilt, nystagmus, ataxia) are more commonly reported in cats, while hearing loss may occur in both dogs and cats and can be irreversible.
• Neuromuscular blockade: Weakness or respiratory depression may occur, particularly in patients with underlying neuromuscular disease or when combined with other neuromuscular blocking agents.
• Injection site reactions: Pain, swelling, or inflammation may occur following IM or SC administration.
• Hypersensitivity reactions: Facial edema and other allergic-type reactions have been reported but are uncommon.
• Gastrointestinal signs: Rare; vomiting or inappetence has occasionally been reported.

Overdose

Overdose or accumulation of amikacin can result in severe and potentially life-threatening toxicity in dogs and cats, particularly involving the kidneys and nervous system.

• Clinical signs: Worsening renal failure, vestibular dysfunction (head tilt, loss of balance), hearing loss, muscle weakness, tremors, or respiratory compromise.
• Management: There is no specific antidote. Treatment consists of immediate discontinuation of the drug, aggressive supportive care, maintenance of hydration, and close monitoring of renal function and neurologic status.
• Dialysis: Hemodialysis can reduce serum drug concentrations but is rarely available in veterinary patients. Peritoneal dialysis may provide limited benefit.
• Consultation: For known or suspected overdose, consultation with a 24-hour veterinary poison control center is strongly recommended.

Key Notes

Practical clinical points to optimize the safe and effective use of systemic amikacin in dogs and cats:

• Serious infection use: Amikacin should be reserved for severe or life-threatening infections where safer antibiotics are ineffective or inappropriate.
• Concentration-dependent killing: Efficacy depends on achieving high peak concentrations, supporting once-daily dosing rather than multiple daily doses.
• Post-antibiotic effect: Bacterial suppression persists even when serum concentrations fall below the MIC, allowing drug-free intervals that may reduce toxicity.
• Culture-guided therapy: Whenever possible, use should be guided by culture and susceptibility testing to avoid unnecessary exposure.
• Hydration status: Maintaining adequate hydration throughout therapy is critical to reduce the risk of drug accumulation and toxicity.
• Monitoring commitment: This drug requires active veterinary monitoring; it is not appropriate for unsupervised or casual use.
• Cats require extra caution: Cats appear more sensitive to vestibular and neurologic toxicity, reinforcing the need for conservative dosing and close observation.
• Client education: Owners should be informed that early detection of subtle changes (balance, hearing, appetite, energy level) can be critical to preventing permanent damage.